Analysis Identifies AbbVie, Abbott, and Coca-Cola as Dividend Kings
Financial analysts designate AbbVie, Abbott Laboratories, and Coca-Cola as high-value long-term investments due to their history of increasing dividends for over 50 years.
Financial analysis in November 2026 identifies AbbVie, Abbott Laboratories Inc, and The Coca-Cola Company as high-value Dividend Kings for long-term investment. These companies are recognized for their ability to increase dividends for at least 50 consecutive years, providing stability amid a volatile macroeconomic environment.
AbbVie has increased its dividend for 55 consecutive years. The company continues to drive value through its immunology drugs Skyrizi and Rinvoq, while developing a pipeline of treatments for cancer and eczema.
Abbott Laboratories Inc is currently restructuring its operations to focus on medical diagnostics and diabetes care. This strategy includes spinning off its nutrition business and integrating the $21 billion acquisition of Exact Sciences, a cancer-focused medical diagnostics company.
The Coca-Cola Company has increased its dividend for 64 consecutive years. The beverage leader recently reached an all-time stock high, maintaining growth as a stable entity within the defensive consumer staples industry.
